Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
135.3 USD | +0.16% | +3.76% | +7.43% |
06-03 | Ascendis Pharma Reports 45% Clinical Response in TransCon IL-2 Phase 1/2 Trial | MT |
06-03 | Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.43% | 7.76B | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.75% | 22.48B | |
-9.35% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- ASND Stock
- News Ascendis Pharma A/S
- Ascendis Pharma A/S : Says FDA Extends PDUFA Action Date for Biologics License Application of Pediatric Growth Hormone Deficiency Drug Candidate